Important limitations you should know For people with normal B12 levels, the evidence is far less compelling
Expert Opin Investig Drugs 32(5):355359 Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S et al (2022) LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Enhanced Keap1-Nrf2 signaling protects the myocardium from isoproterenol-induced pathological remodeling in mice
Peptide studies in children failed to show sustained IGF-1 rises or improvement in final adult height, which is the standard we hold any treatment to
Leckie, G
Preclinical studies demonstrated that dual agonism could achieve greater glucose-lowering effects than either pathway alone